title: The Benefits of Exercise and Metabolic Interventions for the Prevention and Early Treatment of Alzheimer's Disease.
abstract: Alzheimer's disease (AD) is characterized by neuronal degeneration, vascular pathology and cognitive decline. Furthermore, deficits in cerebral glucose metabolism and insulin resistance are being increasingly recognized in AD. Many lifestyle-modifying approaches, including diet and exercise, have yielded promising results in modulating brain morphology and function for the prevention and early treatment of AD.
  
  
  
  This review focuses on the effects of physical exercise on rescuing cognition and limiting the progression of AD pathology. Specifically, the impact of exercise, in human and animal models of AD, on the stimulation and preservation of cognition, neurotransmission, neurogenesis, vasculature, glucose metabolism and insulin signaling is discussed.
  
  
  
  Studies have highlighted the potential of physical activity to improve overall brain health, which could delay or lessen AD-related cognitive deficits and pathology. Physical activity influences cognitive function, vascular health and brain metabolism, which taken together offers benefits for the aging population, including AD patients.
authors.forename: Ewelina
authors.initials: E
authors.lastname: Maliszewska-Cyna
authors.forename: Madelaine
authors.initials: M
authors.lastname: Lynch
authors.forename: Jonathan Jordan
authors.initials: JJ
authors.lastname: Oore
authors.forename: Paul Michael
authors.initials: PM
authors.lastname: Nagy
authors.affiliation: Sunnybrook Research Institute, 2075 Bayview Ave, S112, Toronto, ON, Canada M4N 3M5.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Aubert
mesh_terms: D000544:Alzheimer Disease / Q000378:metabolism* / Q000517:prevention & control / Q000628:therapy*; D000818:Animals; D005081:Exercise Therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin